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ABSTRACT	
Although	randomized	placebo-controlled	trials	(RCT)	are	critical	to	establish	efficacy	of	vaccines	
at	the	time	of	licensure,	important	remaining	questions	about	vaccine	effectiveness	(VE)	–	used	
here	to	include	individual-level	measures	and	population-wide	impact	of	vaccine	programs	--
can	only	be	answered	once	the	vaccine	is	in	use,	from	observational	studies.		However,	such	
studies	are	inherently	at	risk	for	bias.	Using	a	causal	framework	and	illustrating	with	examples	
we	review	newer	approaches	to	detecting	and	avoiding	confounding	and	selection	bias	in	three	
major	classes	of	observational	study	design:	cohort,	case-control,	and	ecological	studies.		
Studies	of	influenza	VE,	especially	in	seniors,	are	an	excellent	demonstration	of	the	challenges	
of	detecting	and	reducing	such	bias,	and	so	we	use	influenza	VE	as	a	running	example.		We	take	
a	fresh	look	at	the	time-trend	studies	often	dismissed	as	“ecological.”	Such	designs	are	the	only	
observational	study	design	that	can	measure	the	overall	effect	of	a	vaccination	program	
(indirect	(herd)	as	well	as	direct	effects),	and	are	in	fact	already	an	important	part	of	the	
evidence	base	for	several	vaccines	currently	in	use.	Despite	the	great	strides	towards	more	
robust	observational	study	designs,	challenges	lie	ahead	for	evaluating	best	practices	for	
achieving	robust	unbiased	results	from	observational	studies.	This	is	critical	for	evaluation	of	
national	and	global	vaccine	program	effectiveness.				
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KEY	MESSAGES	
	
*	Observational	studies	are	a	key	part	of	the	evidence	base	for	the	effects	of	vaccines	(vaccine	
effectiveness,	VE),	especially	at	the	population	level	and	for	rare	but	severe	outcomes	of	
infection,	such	as	death.	Yet	these	study	designs	suffer	from	the	risk	of	bias	due	to	confounding	
and	other	factors.	
	
*	Using	the	illustrative	example	of	influenza	vaccines,	we	show	that	such	biases	can	be	large	
and	describe	three	strategies	--	the	use	of	negative	control	outcomes,	the	use	of	the	test-
negative	design,	and	the	use	of	time-trend	studies	--	to	detect	and	reduce	various	forms	of	bias	
in	observational	studies.	
	
*	Each	of	these	strategies	can	be	very	effective	but	each	depends	on	certain	assumptions	for	
validity,	and	each	may	introduce	new	forms	of	bias	into	the	analysis.	
	
*	Further	work	is	needed	to	develop	best	practices	for	observational	VE	studies	in	the	post-
licensure	period,	possibly	relying	on	a	combination	of	designs	that	may	have	different	forms	of	
bias.	
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INTRODUCTION	
Although	vaccine	 licensure	 requires	evidence	of	 vaccine	 safety	and	efficacy	 from	 randomized	
controlled	trials	(RCT),	many	questions	about	vaccine	effectiveness	(VE)	can	be	answered	only	
by	observational	approaches	after	the	vaccine	is	in	use.	For	example,	the	effects	of	a	vaccine	on	
a	 rare	 outcome,	 such	 as	 mortality,	 can	 typically	 be	 studied	 only	 through	 observational	
approaches.	 Even	 within	 a	 RCT,	 the	 effects	 of	 a	 vaccine	 on	 a	 subgroup	 defined	 after	
randomization	 (and	 therefore	 not	 protected	 by	 randomization	 against	 confounding	 and	
selection	 bias)	 may	 be	 of	 interest;	 such	 subgroup	 analyses	 are	 observational,	 despite	 being	
nested	within	a	RCT.	 	Once	a	vaccine	is	 licensed	and	recommended	for	use,	certain	RCTs	may	
face	ethical	 challenges	 (1)	 ,	 though	 there	may	 remain	VE	questions	of	 interest.	 	 Finally,	RCTs	
randomized	 at	 the	 individual	 level	 are	 designed	 to	 measure	 only	 the	 direct	 protection	 the	
vaccine	 offers	 to	 vaccinated	 persons,	 but	 not	 the	 important	 overall	 effect	 of	 vaccination	 on	
disease	in	the	population,	including	that	achieved	by	indirect	protection	of	unvaccinated	people	
(herd	 immunity).	 Post-licensure	 observational	 studies	 --	 specifically	 ecological	 time-trend	
studies	comparing	population-level	disease	burdens	 in	the	pre-	and	post	vaccination	period	--	
are	 well-suited	 to	 measuring	 indirect	 and	 overall	 effects	 (2-4).	 Such	 studies	 deliberately	
measure	a	different	quantity	from	that	measured	by	individual-level	studies	of	VE,	but	it	is	one	
that	is	highly	relevant	to	policy	making.	
		
VE	may	be	studied	using	any	of	the	three	major	classes	of	observational	study	design:	cohort,	
case-control,	 and	 ecological	 studies.	 Such	 observational	 VE	 assessments	 are	 subject	 to	 the	
effects	of	confounding	and	other	forms	of	bias.	In	particular,	those	who	do	and	do	not	receive	a	
vaccine	may	differ	in	ways	that	affect	the	chance	of	experiencing	the	outcome	(e.g.	mortality	or	
infection).	 If	 so,	 these	 differences	 confound	 the	 measured	 effect	 of	 the	 vaccine	 on	 the	
outcome.	In	this	paper,	we	describe	approaches	to	identify,	address	and	reduce	the	impact	of	
such	confounding	in	observational	VE	studies.	We	provide	examples	of	each	approach	as	well	as	
a	 formal	 account,	 using	 causal	 directed	 acyclic	 graphs,	 of	 how	 each	 approach	 attempts	 to	
address	this	source	of	bias	and	what	assumptions	are	required	for	it	to	be	a	valid	approach.		
	
Specifically,	we	use	a	causal	 framework	 to	describe	 the	 typical	problem	of	confounding	 in	VE	
studies	and	describe	three	approaches	that	have	been	used	to	address	the	problem:	a)	the	use	
of	negative	control	outcomes	in	a	cohort	or	case-control	study,	b)	the	use	of	a	laboratory	test-
negative	control	group	in	a	study	of	all	patients	tested	for	the	infection	of	interest,	and	c)	the	
use	of	an	ecological	 time-trend	design	 to	measure	 indirect	and	overall	 causal	effects	 (5).	Our	
running	example	 is	 the	problem	of	estimating	 influenza	VE,	a	 recently	controversial	area	that	
illustrates	 how	 concerns	 about	 bias	 in	 the	 evidence	 base	 arose,	 how	 these	 approaches	 to	
reduce	or	detect	bias	are	used,	and	how	well	they	address	the	issues	we	are	raising.		Influenza	
VE	 studies	 raise	 nearly	 all	 the	 types	 and	 issues	 of	 potential	 bias,	 and	 all	 the	 strategies	 we	
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discuss	 have	 been	 recently	 applied.	 	 While	 we	 use	 influenza	 VE	 as	 an	 example,	 we	 make	
occasional	reference	to	other	vaccines	for	which	these	strategies	have	been	deployed.	Table	1	
lists	some	of	the	key	substantive	insights	for	multiple	vaccines	that	have	been	gained	from	the	
strategies	we	discuss.	
	
		
THE	GENERAL	PROBLEM	
In	observational	VE	studies	that	compare	outcomes	in	vaccinated	vs.	unvaccinated	persons,	
these	groups	may	differ	in	ways	that	affect	their	risk	of	infection	or	death,	for	reasons	other	
than	their	vaccination	status.	For	example,	those	who	get	vaccinated	may	have	better	access	to	
health	care	for	geographic,	financial	or	other	reasons;	may	be	more	inclined	to	seek	health	
care;	or	may	have	access	to	different	quality	of	care,	for	example	more	preventive	health	care	
services.		Moreover,	vaccinated	persons	may	simply	tend	to	be	healthier	with	high	“functional	
status”,	allowing	them	to	physically	be	able	to	get	to	an	influenza	vaccine	appointment	(6).	Each	
of	these	characteristics	may	be	predictive	of	the	outcome	measured	in	such	studies,	which	may	
be	laboratory-confirmed	infection,	illness	or	mortality	(cause-specific	or	all-cause).		If	not	
adequately	measured	and	adjusted	for	in	analyses,	these	differences	may	confound	the	
association	between	vaccine	receipt	and	the	outcome,	biasing	estimates	of	VE.		
	
This	issue	is	shown	in	Figure	1,	a	causal	directed	acyclic	graph	(DAG)	(7)	showing	the	causal	
connections	among	vaccination	(V),	laboratory-confirmed	infection	(I),	death	(D),	and	various	
confounders	(H,	health	care	access	or	health	status).	Directed	arrows	connecting	these	nodes	
indicate	that	there	is	assumed	to	be	a	direct	effect	of	one	variable	on	another.	The	absence	of	
such	an	arrow	means	that	there	is	assumed	to	be	no	direct	effect	of	one	variable	on	another.	By	
convention,	no	arrow	is	shown	for	the	causal	effect	that	the	study	is	attempting	to	estimate,	
here	the	effect	of	vaccination	on	infection	or	death.	Confounders	of	these	relationships	are	
those	variables	that	affect	whether	an	individual	becomes	vaccinated	(the	exposure	of	interest)	
and	also,	separate	from	the	vaccine	effect,	whether	the	individual	becomes	infected	or	dies	
(the	outcomes	of	interest).	We	wish	to	identify	the	causal	effect	of	the	vaccine	on	infection	or	
death,	and	to	estimate	these	effects	from	the	observed	associations	between	V	and	outcomes	I	
or	D.	To	do	so,	we	must	account	for	potential	confounding	by	H.	For	a	detailed	introduction	to	
how	to	read	such	diagrams,	see	(8).	
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FIGURE	1:	Causal	structure	of	
observational	VE	studies	
showing	the	possible	
confounding	of	the	vaccine	(V)-
outcome	(e.g.	hospitalization	or	
death	D)	relationship	by	health	
status,	health-seeking	behavior	
or	other	characteristics	that	
may	differ	between	those	who	
do	and	do	not	receive	
vaccination.	Any	causal	effect	of	
vaccination	on	D	must	be	
mediated	by	I,	infection	with	the	
pathogen	against	which	the	
vaccine	protects.	
	
THREE	APPROACHES	TO	ADDRESS	BIAS	IN	OBSERVATIONAL	VE	STUDIES	
	
1.	Use	of	negative	controls	to	detect	confounding	in	studies	of	VE	against	mortality	and	other	
severe	outcomes	
	
Identifying	evidence	of	profound	bias	in	cohort	studies	of	influenza	VE.	Influenza	vaccines	were	
developed	in	the	1940s	for	use	in	military	populations	and	have	since	the	1960s	been	used	
mostly	to	vaccinate	the	elderly	despite	early	concerns	that	immunosenescence	may	attenuate	
their	effectiveness	in	old	age	(9).		Once	influenza	vaccines	were	licensed	and	recommended	for	
the	elderly,	it	became	ethically	difficult	to	use	a	placebo-controlled	randomized	trial	design	to	
evaluate	VE	in	this	age	group.	Therefore,	nearly	all	VE	studies	in	the	elderly	have	been	
observational,	using	International	Classification	of	Disease	coded	diagnoses	in	electronic	health	
maintenance	organization	(HMO)	databases	(for	an	exception	see	ref.	(10)).		These	studies	had	
consistently	reported	astonishing	vaccine	benefits	--	that	influenza	vaccination	in	the	elderly	
prevents	as	many	as	50%	of	all	deaths	during	winter	(11-13).		A	decade	ago,	concerns	arose	that	
this	assessment	far	exceeded	what	reasonably	could	be	expected	(6,	14,	15)	and	might	reflect	
uncontrolled	confounding.			
	
Any	causal	effect	of	influenza	vaccination	on	mortality	should	be	evident	only	during	influenza-
epidemic	periods,	usually	in	mid-winter.	Thus,	any	mortality	advantage	among	vaccinees	
occurring	in	the	immediate	pre-epidemic	months	would	indicate	bias,	likely	due	to	confounding	
(6,	16).		To	test	for	the	existence	of	bias,	Jackson	et	al	first	reproduced	in	HMO	data	the	original	
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finding	of	50%	winter	all-cause	mortality	reduction,	then	went	on	to	stratify	the	measurements	
according	to	timing	(pre-,	during,	and	after	influenza).	They	found	that	the	largest	reduction	
occurred	in	the	pre-influenza	period	and	concluded	that	such	studies	had	likely	greatly	
exaggerated	the	true	vaccine	effect.	Later	studies	showed	that	this	confounding	was	
particularly	severe	in	studies	of	all-cause	mortality	but	less	of	a	problem	when	studying	more	
specific	outcome,	such	as	hospitalization	or	mortality	from	pneumonia.	
	
Testing	for	an	effect	of	vaccination	on	an	outcome	that	could	not	plausibly	be	affected	by	the	
vaccine	is	an	example	of	a	more	general	strategy	that	has	been	called	the	“negative	control	
outcome”	strategy.	Though	initially	controversial,	this	bias-detection	approach	is	now	
commonly	used	in	studies	of	influenza	VE	(14,	17-21).		Recent	observational	studies	also	use	
more	specific	endpoints	(e.g.,	pneumonia	hospitalizations	instead	of	all	cause	mortality)	for	
which	VE	can	be	more	reliably	estimated.		The	newer	studies	demonstrated	that	the	VE	against	
these	endpoints	was	in	fact	low	in	seniors,	helping	to	stimulate	the	development	of	more	
immunogenic	vaccines	for	elderly	(19).		
	
A	causal	account	of	the	use	of	negative	control	outcomes	to	detect	bias.	This	finding	inspired	
formal	research	on	the	use	of	this	strategy	for	bias	detection	in	epidemiologic	studies	more	
generally.	This	approach	has	been	termed	a	“negative	control	outcome”	analysis,	by	analogy	to	
laboratory	experiments,	in	which	researchers	include	“negative	controls”	to	verify	that	the	
experimental	system	shows	no	effect	when	it	shouldn’t	(22).		
	
Figure	2	shows	a	modified	DAG	similar	to	that	in	Figure	1,	but	now	including	a	negative-control	
outcome,	death	before	the	influenza	epidemic	period	(D’).	By	assumption,	vaccination	(V)	has	
no	causal	effect	on	death	outside	of	influenza	season,	but	the	common	causes	of	V	and	D	(that	
is,	the	confounders	of	the	V->D	relationship)	should	also	be	causes	of	D’.	In	other	words,	any	
association	between	V	and	D’	should	reflect	pure	confounding,	in	the	absence	of	any	causal	
pathway	from	V	to	D.	Applying	an	analytic	strategy	to	D’	(e.g.,	performing	a	regression	of	the	
mortality	outcome	D’	with	a	particular	set	of	exposures,	focusing	on	the	estimate	of	the	
coefficient	for	V),	and	finding	a	significant	protective	effect	of	V,	indicates	that	the	same	
strategy	applied	to	an	outcome	D	is	likely	to	provide	an	biased	estimate	of	the	causal	effect	of	V	
on	D.	Moreover,	under	certain	assumptions	the	direction	of	bias	should	be	the	same	for	the	
outcome	of	interest	(D)	as	for	the	negative	control	(D’):	in	this	case,	the	measured	VE	against	
death	should	be	biased	upwards	(22).	
	
The	assumptions	underlying	the	valid	use	of	a	negative	control	outcome	are	(i)	that	the	
exposure	does	not	have	a	causal	effect	on	the	negative	control	outcome,	either	directly	or	
indirectly,	and	(ii)	that	all	confounders	of	the	exposure-outcome	relationship	have	the	same	
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causal	effect	on	the	negative	control	outcome	as	they	have	on	the	outcome.	Assumption	1	may	
be	satisfied	if	the	influenza	epidemic	period	is	accurately	characterized	and	if	influenza	
vaccination	has	no	effect,	directly	or	indirectly,	on	mortality	that	is	not	caused	by	influenza	
infection.	Both	of	these	are	plausible	premises	(nonspecific	effects	of	some	vaccines	on	deaths	
not	caused	by	the	pathogen	in	the	vaccine	have	been	reported	(23),	though	not	to	our	
knowledge	for	influenza	vaccine).		Assumption	2	is	reasonable	in	the	temperate	regions	if	those	
factors	that	predict	whether	an	individual	gets	vaccinated	in	say,	early	autumn,	are	equally	
predictive	of	mortality	before	influenza	season	as	during	influenza	season.	
	
		
FIGURE	 2:	 As	 Figure	 1,	 but	 showing	 a	
negative	 control	 outcome	 D’	 (for	 example	
death	outside	of	influenza	season)	that	has	
no	 causal	 connection	 to	 vaccination	 but	
shares	 the	 same	 confounding	 relationship	
with	H	as	the	outcome	of	interest	D.		
	
	
	
	
	
	
The	 use	 of	 negative	 controls	 to	 detect	 the	 existence	 and	 direction	 of	 bias	 has	 several	
advantages.	Under	the	assumptions	above,	negative	control	outcomes	can	detect	confounding	
and	other	forms	of	bias,	even	if	the	investigator	has	not	identified	the	likely	source	of	the	bias	
ahead	 of	 time.	 	 Similarly,	 if	 one	 has	 identified	 a	 potential	 confounder	 of	 the	 relationship	 of	
interest	 and	 wants	 to	 know	 whether	 it	 has	 been	 adequately	 controlled	 in	 an	 analysis,	 the	
analysis	can	be	applied	to	a	negative	control	outcome	to	find	out.		Indeed,	Jackson	et	al.	did	just	
that	to	test	the	adequacy	of	“standard”	statistical	approaches	(multiple	regression	modeling)	to	
controlling	 for	 health	 status	 in	 the	 elderly,	 and	 found	 that	 those	 had	 in	 fact	 been	
counterproductive	and	had	exacerbated	the	overestimate	of	VE	(6).		
	
The	principal	 limitation	of	 the	 negative	 control	 outcome	approach	 is	 that	 it	 does	 not	 offer	 a	
straightforward	 formula	 to	 correct	 for	 these	biases.	 It	 can	urge	 caution	but	 cannot	 solve	 the	
problem	 it	 identifies.	 However,	 identifying	 the	 bias	 may	 be	 a	 first	 step	 toward	 refining	 the	
analysis	to	reduce	it;	these	refined	analyses	may	then	be	submitted	to	negative	control	analyses	
to	 see	 if	 the	problem	has	been	 resolved.	 	Work	 is	underway	 to	expand	 the	 idea	of	negative-
controls	to	correct	for,	rather	than	just	detect,	biases	(24,	25).		
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2.	Test-negative	designs	
		
Confounding	in	studies	of	VE	against	clinically	apparent	infection.	To	assess	VE	against	clinically	
attended	 infection,	 investigators	 often	 choose	 the	 case-control	 design	 for	 its	 ability	 to	 give	
results	 rapidly	and	with	moderate	sample	sizes.	As	 in	other	observational	designs,	vaccinated	
and	unvaccinated	persons	may	differ	 in	systematic	ways	that	may	 lead	to	confounding	of	the	
vaccine’s	 effect.	 An	 increasingly	 popular,	 convenient	 and	 cost-saving	 approach	 to	 such	 VE	
studies	 is	 the	 use	 of	 a	 "test-negative"	 control	 group.	 	 While	 “cases”	 in	 such	 studies	 are	
individuals	with	a	defined	clinical	syndrome	who	test	positive	 for	 the	pathogen	for	which	the	
vaccine	 is	 designed,	 “test-negative”	 controls	 are	 those	with	 the	 same	 clinical	 syndrome	who	
had	tested	negative	(1).	This	novel	approach	goes	by	different	names	and	is	sometimes	seen	as	
a	variant	of	the	case-control	approach	(26).	Because	it	differs	from	a	case-control	study	in	that	
participants	 are	 ascertained	 prior	 to	 knowledge	 of	 their	 outcome,	 without	 a	 fixed	 ratio	 of	
outcomes	in	the	study	(27),	it	could	be	seen	as	a	type	of	cohort	study;	indeed,	arguably	the	first	
test-negative	 vaccine	 study	 was	 called	 an	 “indirect	 cohort”	 study	 (28).	 To	 avoid	 semantic	
confusion	we	simply	call	it	the	test-negative	design.	The	motivating	idea	for	the	design	is	that,	if	
a	major	source	of	confounding	in	the	vaccination-disease	relationship	is	a	differential	tendency	
to	 seek	health	 care	when	 ill	 between	 those	who	get	 vaccinated	and	 those	who	do	not,	 then	
limiting	the	analysis	to	those	who	have	sought	health	care	for	a	similar	illness	should	reduce	or	
eliminate	this	source	of	confounding.		
		
It	has	over	the	last	decades	become	established	practice	in	the	US,	Canada	and	Europe	to	base	
influenza	VE	estimates	on	such	test-negative	studies	conducted	during	and	immediately	after	
each	influenza	season.		The	“cases”	and	“test-negative	controls”	both	sought	care	for	an	
influenza-like	illness,	typically	defined	as	fever	plus	respiratory	symptoms	(17,	26,	29-31),	and	
the	test-negative	controls	are	those	who	test	negative	on	the	real-time	reverse-transcriptase	
polymerase	chain	reaction	(rRT-PCR)	test	for	influenza	virus.		
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	FIGURE	3:	Causal	diagrams	of	the	test-negative	design.	Here,	the	outcome	of	interest	is	laboratory-
confirmed	clinically	attended	influenza	infection	(T+).		A.	As	before,	health	seeking	behavior	or	other	
characteristics	H	may	differ	between	those	who	do	and	do	not	receive	vaccination,	and	may	affect	the	
probability	of	receiving	a	test	for	influenza	(T)	through	other	confounding	pathways	(H->T).	The	test-
negative	design	conditions	on	T	by	including	only	those	who	are	tested,	and	thereby	blocks	this	
confounding	effect.	B.	However,	this	conditioning	creates	selection	bias,	a	noncausal	association	(orange	
line	1)	between	health-seeking	behavior	and	infection,	by	conditioning	on	their	common	effect,	biasing	
the	V->T+	association.	C.	The	test-negative	design	in	greater	detail,	including	two	time	periods	(e.g.	
consecutive	weeks)	in	which	individuals	are	enrolled.	The	study	is	intended	to	measure	protection	by	the	
pathways	shown	in	green.	Bias	may	occur	if	(arrow	2a)	vaccination	has	a	short-term,	nonspecific	effect	
on	other	infections	N,	or	(arrow	2b)	if	influenza	is	temporarily	protective	against	other	infections	N,	or	
(arrow	2c)	if	influenza	is	protective	against	influenza	later	in	the	season.	D.	The	test-negative	design	does	
not	protect	(nor	does	the	“classic”	case-control	design)	against	confounding	effects	in	which	some	factor	
G	(e.g.	being	a	health	care	worker)	is	a	common	cause	of	both	getting	vaccinated	and	getting	infected	
given	vaccination	status.	
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A	causal	account	of	the	test-negative	design	
	
The	use	of	test-negative	controls	means	that	we	are	not	studying	the	relationship	between	
vaccine	(V	in	Figure	3A)	and	influenza	infection	(I),	but	the	relationship	between	vaccine	and	
testing	positive	for	influenza	(T+)	among	those	who	are	tested	(T).	In	our	expanded	causal	
diagram	for	this	design,	we	also	include	other	factors	that	affect	whether	an	individual	gets	
tested	for	influenza	(N),	such	as	other	infections.	Figure	3A	illustrates	that	by	conditioning	on	
testing,	we	block	the	confounding	effect	of	health-care	seeking	behavior	(H,	whether	measured	
or	not)	on	the	vaccination-influenza-positive	relationship.	In	the	language	of	causal	DAGs,	we	
block	the	back-door	path	between	vaccination	and	the	outcome	V<H>T>T+.	
	
The	advantage	of	avoiding	this	form	of	confounding	is	balanced	by	several	disadvantages,	which	
can	also	be	understood	in	the	context	of	a	causal	diagram	and	are	shown	by	the	numbered	
arrows	in	Figures	3B-D.	We	have	added	further	arrows	(shaded	orange	for	clarity),	each	
representing	one	of	the	concerns	described	below.		
	
Concern	#1:	Selection	bias	introduced	by	limiting	consideration	to	those	tested.		Both	influenza	
infection	and	health	care	seeking	behavior,	by	assumption,	influence	the	probability	of	being	
tested	for	influenza.	The	use	of	test-negative	controls	is	equivalent	to	conditioning	the	analysis	
on	testing,	which	is	a	common	consequence	of	both	health-seeking	behavior	and	influenza	
infection.	This	induces	a	correlation	among	the	tested	persons	between	their	health	seeking	
behavior	and	influenza	positivity,	which	induces	selection	bias	in	the	estimate	of	VE	(32).	This	
form	of	selection	bias	or	”collider	bias”,	correlation	between	the	two	causes	of	a	common	
effect	when	conditioning	on	that	common	effect	is	shown	as	a	dashed	line	(Line	1,	Figure	3B).		
	
Concern	#2:	Bias	due	to	measurement	of	effects	other	than	those	directly	through	preventing	
influenza.		The	scientific	goal	of	VE	studies	is	to	measure	the	direct	effect	of	influenza	
vaccination	on	preventing	clinically	attended,	laboratory-confirmed	influenza	infection.	If	the	
vaccine	has	other	effects	that	can	mimic	or	mask	this	direct	effect,	then	the	effect	will	be	
overestimated	or	underestimated,	respectively.		
	
Figure	3C	illustrates	these	biases,	expanding	Figure	3A	to	show	that	VE	studies	take	place	over	
time	–	in	the	case	of	influenza	VE	studies,	usually	over	a	full	season.	For	simplicity	we	show	only	
two	time	points,	1	and	2,	which	might	be	consecutive	weeks	during	the	season.	The	arrows	
shown	in	cyan	indicate	the	pathways	through	which	the	test-negative	design	is	meant	to	
estimate	VE,	through	the	effect	on	preventing	influenza	infection.	If	a	person	is	less	likely	to	
become	influenza-infected,	s/he	is	less	likely	to	seek	testing	and	less	likely,	if	tested,	to	test	
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positive	for	influenza.	The	orange	arrows	show	three	pathways	by	which	this	effect	could	be	
biased.		
	
The	first	such	potential	source	of	bias	occurs	if	the	seasonal	influenza	vaccine	has	an	effect	(for	
example	protective)	on	non-influenza	conditions	that	present	with	influenza-like	symptoms.	In	
this	case	vaccination	could	cause	someone	to	be	less	likely	to	be	a	control	than	a	typical	
member	of	the	general	population	(Arrow	2a).	Typically,	it	is	assumed	that	this	cannot	happen	
because	influenza	vaccines	confer	antigen-specific	immunity	that	should	be	protective	only	
against	influenza.	Yet	at	least	some	influenza	vaccines	induce	innate,	non-specific	antiviral	
immune	responses	(33)	that	could	reduce	the	risk	of	other	viral	infections	for	a	short	period	of	
time	after	immunization,	possibly	an	example	of	a	more	general	phenomenon	(34).	Graphically,	
this	corresponds	to	a	pathway	by	which	vaccination	increases	the	probability	of	testing	positive	
among	those	tested,	not	via	any	effect	on	influenza,	but	by	reducing	the	frequency	of	other	
conditions	that	to	testing,	V->N->T+.	If	this	occurs,	the	test-negative	design	will	be	biased	to	
show	less	protective	effect	against	influenza	because	some	of	the	benefit	is	hidden	by	
protection	against	other	infections.	
	
The	second	such	potential	source	of	bias	occurs	if	influenza	infection	itself	induces	nonspecific	
protection	against	later	acquiring	non-influenza	infections	(Arrow	2b).	In	this	case,	the	vaccine’s	
protection	against	influenza	in	any	given	week	could	increase	the	risk	of	non-influenza	
respiratory	infection,	and	hence	of	being	a	test-negative	participant,	in	a	subsequent	week	
(Arrow	2b).	There	is	some	evidence	for	such	an	effect	(35).	This	bias	will	occur	only	if	there	is	a	
true	benefit	of	influenza	vaccine	against	influenza	infection,	but	will	lead	to	an	overestimate	of	
this	protection	because	vaccinated	individuals	will	be	less	likely	to	appear	in	the	control	group	
than	in	the	general	population.	Graphically,	if	the	vaccine	has	some	effectiveness	against	
influenza	infection,	there	will	be	a	path	V->I1->N2->T+	that	includes	an	effect	the	study	is	not	
designed	to	measure.	
	
The	third	such	potential	source	of	bias	occurs	because	people	who	get	influenza	once	in	a	
season	are	usually	immune	to	getting	it	again	that	season	(36)	(Arrow	2c).	Therefore	as	the	
influenza	season	progresses,	if	the	vaccine	is	effective,	persons	at	high	risk	of	influenza	infection	
will	be	removed	more	rapidly	from	the	unvaccinated	than	the	vaccinated	group,	and	the	
apparent	effectiveness	will	decline	over	the	course	of	the	season	(37).	Thus	the	within-season	
immunity	will	attenuate	VE	estimates	over	the	course	of	the	season,	if	the	vaccine	is	effective.	
This	appears	to	have	happened	in	the	2012-3	influenza	season	in	the	US,	where	VE	estimates	
declined	over	the	course	of	the	season	(38-40).	This	source	of	bias,	unlike	the	previous	two,	
occurs	even	with	an	“ordinary”	case-control	design,	as	it	does	not	depend	on	the	choice	of	
controls	but	rather	on	the	fact	that	influenza	is	an	immunizing	infection.	The	graphical	
representation	of	this	bias	is	the	path	V->I1->I2->T+.	
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Concern	#3:	residual	healthy	vaccinee	effects.		The	use	of	test-negative	controls	will	eliminate	
confounding	that	arises	because	vaccinated,	influenza	infected	people	have	a	different	
probability	of	getting	tested	from	unvaccinated,	influenza-infected	people	--	for	example	
because	they	are	greater	users	of	health	care	services.	However,	those	who	get	vaccinated	may	
also	be	more	likely	to	get	influenza	than	those	who	don’t,	for	example	because	of	their	age	or	
geography.	We	indicate	such	confounding	with	a	new	factor	G	in	Figure	3D,	which	plausibly	
affects	risk	of	both	influenza	and	other	infections.	If	these	other	factors	are	not	separately	
controlled	for,	the	use	of	test-negative	controls	will	not	remove	their	confounding	effects.	This	
problem	arises	whether	conventional	controls	or	test-negative	controls	are	used,	so	is	not	
unique	to	the	test-negative	design;	we	mention	it	merely	to	highlight	that	it	is	not	solved	by	the	
test-negative	design.	
	
Concern	#4:	misclassification	of	false-negative	cases	as	controls.		Use	of	any	diagnostic	test	for	
the	identification	of	cases	and	controls	has	the	potential	of	misclassification.		Imperfect	
sensitivity	of	the	diagnostic	test	leads	to	false	negatives,	so	that	some	who	should	have	been	
cases	become	controls.		Imperfect	diagnostic	test	specificity	allows	true	influenza-negative	
individuals	to	become	misclassified	as	cases.	Either	form	of	measurement	error	may	lead	to	
attenuation	of	VE	estimates.	A	recent	simulation	study,	however,	indicates	that	with	realistic	
values	of	VE	and	currently	available	influenza	tests,	the	magnitude	of	this	bias	is	negligible	(41).			
	
Notwithstanding	the	possibility	of	all	of	these	forms	of	bias,	test-negative	studies	have	reported	
plausible	results,	including	very	low	or	no	effectiveness	of	severely	mismatched	vaccine	
formulations	for	certain	seasons	such	as	2014-15	(42-44)	and	for	elderly	in	multiple	seasons	
(30,	40).		The	test-negative	study	design	was	used	in	a	study	that	argued	that	receipt	of	
seasonal	influenza	vaccine	was	associated	with	increased	risk	of	H1N1pdm	morbidity	during	the	
2009	pandemic	period	in	Canada	(17)	It	was	also	used	to	demonstrate	that	live	attenuated	
vaccine	was	less	effective	than	TIV	in	adults	(45)	and	children	(46).		Finally,	IMOVE,	a	large	
multi-country	European	study,	routinely	uses	the	case-negative	approach	to	produce	one	
pooled	influenza	VE	estimate	during	each	season	across	Europe	(47).		
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3.	Time-Trend	VE	studies		
	
Time-trend	 study	 designs	 offer	 another	 approach	 to	 avoid	 some	 forms	 of	 confounding	 in	 VE	
studies.	These	studies,	which	are	ecological	in	design,	do	not	compare	the	incidence	of	infection	
or	other	outcomes	in	vaccinated	vs.	unvaccinated	persons,	so	they	are	not	subject	to	the	kinds	
of	confounding	by	health	status	or	health-seeking	behavior	described	in	the	previous	sections.	
Instead,	 they	 estimate	 the	 reduction	 in	 an	 outcome	 following	 vaccine	 introduction	 in	 a	
population,	 where	 the	 outcome	 is	 measured	 in	 individuals	 (who	 either	 die	 or	 survive)	 but	
summed	over	the	whole	population.	Thus,	such	studies	estimate	the	effect	of	a	change	in	the	
proportion	vaccinated	in	a	population	on	the	frequency	of	that	outcome	in	the	population	–	a	
causal	 quantity	 of	 policy	 relevance.	 Such	 studies	have	been	widely	used	 to	demonstrate	 and	
quantify	 the	 effect	 of	 vaccines	 including	 pneumococcal	 conjugate	 vaccines	 (2,	 29,	 48,	 49),	
Haemophilus	influenzae	type	b	conjugate	vaccines,	influenza	vaccines	(3,	15,	50),	and	rotavirus	
vaccine	(51).	
	
Time-trend	 VE	 studies	 aim	 to	measure	 a	 different	 quantity	 from	 the	 VE	 that	 is	 estimated	 in	
individual-level	 studies	 such	 as	 cohort	 and	 case-control	 studies.	 The	 impact	 of	 changing	
coverage	of	a	vaccine	 in	a	population	 is	of	considerable	 interest	to	policy	makers,	who	would	
like	 to	 know	 the	 number	 of	 cases	 that	 would	 be	 prevented	 under	 a	 vaccination	 program	
targeting	a	particular	 segment	of	 the	population.	Among	observational	designs,	 an	ecological	
study	 is	 uniquely	 appropriate	 to	measure	 exactly	 this	 quantity.	 For	 contagious	 diseases,	 the	
impact	 of	 vaccinating	 a	 substantial	 segment	 of	 the	 population	 will	 be	 a	 combination	 of	 the	
protection	 to	 vaccinees,	 and	 indirect	 (“herd	 immunity”)	 protection	 for	 those	 who	 are	 not	
immunized.	Here	the	terms	direct	and	indirect	are	used	in	their	infectious	disease	sense,	which	
differs	 from	 that	 typical	 in	 the	 causal	 inference	 literature	 (52).	 In	 infectious	 diseases	we	 use	
indirect	 protection	 to	 refer	 to	 the	 phenomenon	 that	 preventing	 infection	 in	 the	 vaccinated	
members	of	the	population	reduces	infection	risk	to	those	who	are	unvaccinated	(53).	In	Figure	
4,	we	provide	a	modified	causal	diagram	that	includes	the	same	elements	as	Figure	1,	with	the	
addition	of	year	(Y),	vaccine	coverage	(C).		We	do	not	consider	more	than	one	year,	reflecting	
the	 assumption	 that	 vaccination	 and	 infection	 dynamics	 in	 one	 year	 do	 not	 affect	 those	 in	
future	 years.	 This	 is	 a	 simplification	 but	 a	 commonly-made	 one	 for	 influenza;	 relaxing	 this	
assumption	would	involve	complexity	beyond	our	scope.	We	show	the	hypothesized	routes	of	
vaccine	coverage	effect	on	infection:	direct	effects	on	the	vaccinees	(C>V>I)	and	indirect	effects	
through	 the	 vaccine	 status	 of	 other	members	 of	 the	 community	 on	 the	 infection	 risk	 of	 an	
individual	(C>V’>I)	Often	the	outcome	measured	is	mortality	or	hospitalization	(D).	
	
By	estimating	 the	causal	effect	of	 coverage	on	 the	 total	number	of	outcomes	of	 interest	 (for	
example,	 pneumonia	 deaths	 when	 focusing	 on	 influenza	 vaccine),	 a	 time-trend	 study	
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circumvents	the	confounding	by	individual	health-seeking	behaviors	H	that	affects	other	study	
designs;	H	is	by	assumption	not	a	confounder	of	the	relationship	between	coverage	(which	can	
be	interpreted	as	the	average	probability	of	vaccination	in	the	population)	and	the	outcome.	
	
Time-trend	studies	may	be	used	to	study	the	overall	effect	of	vaccination,	that	is	the	reduction	
in	average	risk	for	a	person	in	a	vaccinated	population	with	a	given	level	of	coverage,	compared	
to	a	person	in	an	unvaccinated	population	(54,	55).	Moreover,	it	may	be	limited	to	age	groups	
that	 are	 not	 eligible	 for	 vaccination,	 studying	 the	 indirect	 effect	 of	 the	 vaccine,	which	 is	 the	
impact	 of	 increased	 vaccine	 coverage	 in	 one	 age	 group	 on	 outcomes	 in	 another	 (3).	 This	
approach	 has	 also	 been	 used	 to	 study	 the	 indirect	 (herd	 immunity)	 benefits	 of	 infant	 PCV	
vaccine	use	as	a	way	to	protect	adults	(29,	49,	55,	56).		
	
For	 influenza,	 researchers	 in	 several	 countries	 used	 a	 time-trend	 study	 to	 estimate	 the	
reduction	 in	pneumonia	and	 influenza	mortality	 in	elderly	over	 a	 few	decades	as	 vaccination	
coverage	 in	 this	 age	 group	 increased	 from	 marginal	 to	 over	 65%	 --	 but	 failed	 to	 see	 any	
downward	 trends	 (15,	 57).	 It	was	 these	 studies	 that	 led	 to	 a	 re-examination	of	 the	evidence	
base	 from	 other	 observational	 studies	 that	 had	 reported	 astonishing	mortality	 benefits	 (14).			
Ultimately	 all	 of	 these	 efforts	 led	 to	 the	 understanding	 that	 more	 immunogenic	 vaccine	
formulations	may	be	needed	 for	 seniors,	 and	 the	 renewed	 interest	 in	pursuing	 strategies	 for	
influenza	control,	such	as	the	vaccination	of	“transmitters”	 including	children	to	achieve	herd	
protection	of	elderly	(58).	
FIGURE	4:	 In	 a	 time-trend	 study	 of	 vaccine	 effects,	
year	 (Y)	 affects	 vaccine	 coverage	 C,	 which	 can	 be	
interpreted	 as	 each	 individual’s	 risk	 of	 being	
vaccinated	V.	Coverage	also	affects	the	vaccination	
status	 of	 contacts	 V’,	 which	 affects	 (through	 herd	
immunity)	 an	 individual’s	 infection	 risk.	 The	
association	 between	 coverage	 and	 the	 outcome	 D	
(typically	 a	 severe	 one,	 such	 as	 pneumonia	 or	
death)	will	be	causal	if	year	is	affecting	the	outcome	
only	 through	 vaccine	 coverage	 and	 not	 through	
other	 paths	 such	 as	 development	 –	 that	 is,	 if	 the	
orange	arrow	is	absent.	
	
Conditions	for	the	validity	of	time-trend	VE	studies	
	
Ecological	study	designs	have	been	justifiably	criticized	when	the	question	of	interest	is	how	a	
particular	 exposure,	 such	 as	 vaccination,	 affects	 an	 individual’s	 risk	 of	 an	 outcome,	 such	 as	
death.	The	term	“ecological	fallacy”	is	used	to	describe	the	problem	with	ecological	studies	that	
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aim	to	estimate	such	individual-level	quantities.	However,	this	line	of	criticism	does	not	apply	to	
ecological	VE	studies,	properly	interpreted,	because	they	do	not	aim	to	make	inferences	about	
individual	 vaccination	 and	 individual	 risk,	 but	 rather	 about	 the	 impact	 of	 changing	 vaccine	
coverage	on	the	risk	of	a	group	of	people.	
	
Thus	an	ecological	study	comparing	outcomes	in	populations	with	different	levels	of	coverage	
may	be	considered	as	the	non-randomized	analog	of	a	cluster-randomized	trial.	An	ecological	
VE	study	may	compare	incidence	within	a	single	population	in	different	years	where	vaccination	
coverage	was	different,	or	across	different	populations	with	different	levels	of	coverage.	In	this	
respect,	an	ecologic	study	design	 is	 the	proper	observational	study	design	to	estimate	overall	
vaccine	 effects.	 	 Like	 other	 observational	 studies,	 this	 design	 may	 suffer	 from	 confounding	
when	populations	that	have	different	levels	of	vaccine	coverage	also	differ	in	incidence	of	the	
outcome	 for	 reasons	 separate	 from	 the	 level	of	 vaccine	 coverage.	These	 confounding	 factors	
may	 include	 the	 age-distribution	 of	 the	 population,	 economy/development	 (which	 may	
influence	both	vaccine	coverage	and	risk	of	severe	outcomes	of	an	illness),	the	recent	incidence	
of	the	disease	in	the	population	(which	might	affect	the	prevalence	of	natural	immunity	to	the	
disease),	 or	 the	 extent	 of	 co-circulation	 of	 other	 agents	 that	 can	 affect	 the	 outcome	 (for	
example,	bacterial	infections	that	can	lead	to	complications	of	influenza	infection).	Such	factors	
may	confound	estimates	of	VE,	because	they	imply	that	year	(in	our	example)	has	an	effect	on	
the	outcome	through	some	variable	other	than	vaccine	coverage	(there	may	be	an	arrow	from	
Y	 directly	 to	 D).	 In	 such	 a	 situation,	 it	 may	 be	 possible	 anticipate	 the	 direction	 of	 the	 bias	
induced	by	 such	 confounding,	 or	 even	 to	measure	 and	 adjust	 for	 it;	 for	 example,	 population	
aging	or	comparison	of	communities	with	different	age	structures	could	be	improved	by	using	
age-standardized	 mortality	 rather	 than	 crude	 mortality	 (15).	 Likewise,	 adjusting	 for	 the	
expected	reduction	in	severe	infection	outcomes	as	a	result	of	socio-economic	development	is	
needed	when	studies	are	set	in	lower	and	middle	income	countries	(59).	Practically,	if	baseline	
data	on	the	outcome	are	available	for	a	period	before	the	vaccine	is	introduced,	evidence	of	a	
trend	 prior	 to	 vaccine	 introduction	 could	 be	 accounted	 for	 analytically,	 though	 there	 is	 no	
guarantee	 that	 extrapolating	 the	 pre-vaccine	 trend	will	 accurately	 capture	what	would	 have	
happened	without	the	vaccine.		
	
These	considerations	also	urge	caution	about	the	external	validity	of	a	time-trend	study	of	VE.	
The	proportion	of	a	nonspecific	outcome	preventable	with	a	particular	vaccine	will	depend	on	
the	mix	of	causes	of	that	outcome.		For	example,	a	vaccine	against	any	individual	pathogen	that	
causes	pneumonia	will	likely	prevent	a	changing	proportion	of	childhood	pneumonia	deaths	as	
a	 population	 goes	 through	 epidemiologic	 transition	 and	 profoundly	 lower	 background	
childhood	mortality	(59).		
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An	important	consideration	of	time-trend	VE	studies	 is	 that	the	disease	or	mortality	outcome	
under	 study	 must	 be	 sufficiently	 specific	 so	 that	 the	 vaccine’s	 impact	 on	 it	 is	 likely	 to	 be	
measurable.	For	most	vaccines,	all-cause	mortality	is	so	nonspecific	that	the	true	causal	effect	
of	 an	 effective	 vaccine	would	be	expected	 to	be	only	marginal,	making	 a	 true	effect	 hard	 to	
discern.	 	 Moreover,	 should	 other	 non-vaccine	 changes	 occur	 they	 are	 more	 likely	 to	 cause	
confounding,	resulting	in	misattribution	to	the	vaccine	of	other	causal	factors	affecting	general	
mortality.		
	
	
DISCUSSION	
	
Global	vaccine	efforts	continue	to	expand	thanks	to	the	Expanded	Program	on	Immunization	
(EPI)	(60)	and	the	continuous	arrival	of	new	vaccines		(rotavirus,	HPV,	PCV,	and	others).		Given	
the	need	for	ongoing	evaluation	of	VE	of	all	these	vaccines	as	they	are	introduced	in	new	
geographic	areas	and	in	new	population	segments,	exclusive	reliance	on	evidence	from	
randomized	trials	is	impractical	for	ethical,	logistical	and	economic	reasons,	and	is	
unsatisfactory	because	severe	outcomes	of	most	interest	for	policy	purposes	are	rarely	studied.			
Therefore	the	evidence	base	is	typically	built	on	post-introduction	(phase	IV)	observational	
studies,	studies	characterized	by	a	risk	of	bias	due	to	confounding	when	differences	between	
vaccinated	and	unvaccinated	persons	are	not	adequately	measured	and	adjusted	for.		Many	
such	observational	studies	are	performed	each	year,	but	there	has	been	no	systematic	
assessment	of	the	conditions	under	which	particular	study	designs	are	to	be	preferred,	or	how	
disparate	results	should	be	compared.		Toward	that	end,	we	have	presented	an	overview	of	
three	of	the	most	important	approaches	to	improving	the	reliability	of	observational	studies	for	
estimating	VE.		Using	the	framework	of	causal	inference	and	the	tool	of	causal	DAGs,	we	have	
identified	conditions	under	which	each	of	these	study	designs	is	valid,	and	thereby	conditions	
under	which	they	may	be	biased.	Importantly,	the	existence	of	a	possible	bias	does	not	imply	
that	this	bias	will	be	large	relative	to	the	effect	being	estimated.	As	a	corollary,	the	number	of	
potential	biases	identified	for	a	particular	design	is	not	an	indicator	of	the	design’s	desirability,	
as	these	biases	may	be	of	trivial	magnitude	in	particular	cases.		Some	work	has	been	done,	but	
more	work	is	needed,	to	estimate	the	likely	magnitude	of	these	biases	(26,	27,	41,	61-63).	Such	
work	is	important	because	of	the	high	reliance	on	such	studies	to	provide	of	the	evidence	base	
used	to	set	vaccine	policy..		
	
Failure	to	account	for	such	biases	has	led	to	large	errors	in	the	estimates	of	vaccine	effects	in	
observational	studies,	and	that	these	errors	may	be	amplified	as	they	gain	authority	and	
apparent	precision	through	the	process	of	systematic	review	and	meta-analysis.			A	now	well	
established	example	of	this	comes	from	influenza	VE	literature,	in	which	most	of	the	published	
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observational	studies	up	to	2005	or	so	were	afflicted	with	unadjusted	confounding	that	had	led	
to	profound	overestimation	of	vaccine	benefits	in	seniors	(14).	That	flawed	evidence	base	had	
suggested	that	1	death	could	be	saved	by	vaccinating	150-300	elderly	-	when	in	fact	seniors	
respond	poorly	to	influenza	vaccine.		Once	the	cohort	study	designs	had	been	improved	and	
bias	detection	strategies	incorporated	(17,	18,	62)	earlier	reports	of	astonishing	mortality	
savings	were	replaced	with	the	insight	that	these	studies	suffered	from	confounding	that	led	to	
dramatic	VE	overestimation.	This	finding	was	reinforced	by	evidence	from	a	trend	study	of	
modest	effects	at	the	population	level	(15).	We	have	discussed	three	approaches	to	avoiding	or	
circumventing	such	bias	in	observational	studies	--		but	each	involves	tradeoffs.	Characteristics	
of	the	three	approaches	are	summarized	in	Table	2.	
	
Firstly,	the	use	of	negative	controls	in	an	observational	study	can	be	a	powerful	way	to	detect	
bias,	but	only	if	the	relationship	between	confounders	and	the	negative	control	outcome	
closely	resembles	the	relationship	with	the	outcome	of	interest,	and	if	there	are	no	other	
sources	of	association	between	vaccination	and	the	negative	control	outcome.	The	use	of	pre-
influenza	mortality	as	a	negative	control	outcome	is	particularly	suitable	because	there	is	strong	
biological	plausibility	to	these	assumptions,	but	in	other	situations	(in	particular	for	non-
seasonal	diseases)	the	available	negative	control	outcomes	may	be	more	open	to	question.	
Further	efforts	are	needed	to	define	operationally	how	negative	control	outcomes	can	best	be	
selected.	Meanwhile,	we	can	perhaps	think	of	the	negative	control	outcomes	as	“sensibility	
analyses”;	more	than	typical	sensitivity	analyses	these	are	meant	to	add	biological	meaning	to	
the	exploration	of	robustness	of	the	VE	findings.	
	
Secondly,	the	test-negative	approach	is	now	widely	used	to	provide	timely	and	accurate	VE	
estimates	from	laboratory-based	surveillance	data.		The	upside	of	test-negative	studies	is	that	
they	can	eliminate	important	confounding	effects	of	health-seeking	behavior,	but	the	downside	
is	that	they	do	so	at	the	cost	of	risk	of	selection	bias	that	leads	to	a	non-causal	association	
between	health-care	seeking	behavior	and	infection	with	the	pathogen	of	interest.	Moreover,	
this	design	requires	that	neither	the	infection	of	interest,	nor	the	vaccine	of	interest,	affects	the	
probability	of	other	infections	that	may	lead	someone	to	be	a	test-negative	control.	These	
assumptions	are	questionable	in	many	circumstances,	though	the	evidence	is	limited	for	most	
infections.	We	suspect	that	the	downsides	of	the	test-negative	approach	will	often	be	
outweighed	by	the	advantages	of	avoiding	confounding	by	health-care	seeking	behavior,	but	
additional	simulation	studies	may	help	to	throw	light	on	the	magnitude	of	potential	biases.	
Meanwhile,	it	will	often	be	possible	to	include	both	test-negative	controls	and	other	control	
groups	that	have	different	properties.	Consistent	results	from	such	comparisons	will	be	
reassuring.	
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Thirdly,	time-trend	studies	are	often	used	to	demonstrate	benefits	of	vaccine	programs.		The	
advantages	are	that	these	are	by	design	free	of	confounding	due	to	individual	differences	by	
studying	rates	in	the	whole	population,	and	uniquely	address	the	important	question	of	the	
overall	population-level	effect	of	vaccine	coverage	(different	from	case-control	and	cohort	
studies	that	can	only	measure	the	direct	VE).		The	main	disadvantage	is	that	these	studies	are	
prone	to	their	own	forms	of	confounding,	if	other	factors	besides	vaccine	coverage	that	affect	
the	outcome	are	changing	over	time	along	with	vaccine	coverage.	Such	confounding,	if	
measured,	may	be	demonstrated	by	the	use	of	negative	control	outcomes,	and	adjusted	for	in	
various	ways.		Despite	being	somewhat	unfairly	stigmatized	for	being	“ecological”,	this	class	of	
studies	is	appropriately	prominent	in	the	evidence	base	because	of	the	importance	of	
measuring	population-level	effects,	especially	on	outcomes	that	are	too	rare	to	measure	in	
most	RCTs.			
	
The	approaches	to	address	bias	in	observational	studies	described	here	can	be	combined	or	
blended.	For	example,	time-trend	studies	were	used	to	investigate	the	impact	of	pneumococcal	
conjugate	vaccine	on	respiratory	hospitalizations,	and	investigators	used	various	negative	
control	outcomes,	such	as	dehydration	(64)	and	urinary	tract	infection	(49)	hospitalizations,	to	
rule	out	other	population-level	trends	that	could	have	affected	hospitalization	rates	in	general.				
	
In	another	example,	several	VE	case-control	studies	for	cholera	vaccines	have	used	confirmed	
cholera	diarrhea	as	cases	and	chose	as	controls	persons	who	did	not	seek	treatment	for	
diarrhea	–	a	conventional	design	(65-67).	They	then	did	a	parallel	”bias-indicator”	analysis	using	
those	who	sought	treatment	for	diarrhea	but	did	not	test	positive	for	cholera	as	cases	and	
conventional	controls,	showing	that	the	study	design	did	not	find	measurable	VE	for	a	non-
cholera	outcome.	This	negative	control	outcome	approach	has	an	obvious	similarity	to	the	test-
negative	design.	
	
Considering	importance	given	of	positive	evidence	from	trends	studies	(4,	49,	64,	68,	69)	in	
shaping	vaccine	policy,	and	given	that	the	time-trend	study	design	is	the	only	one	to	capture	
the	overall	benefits	of	a	vaccine	program,	it	is	critical	that	much	effort	goes	into	the	
identification	of	strategies	for	bias	detection	and	bias-elimination	and	to	the	validation	of	
findings	and	elimination	of	any	other	explanation	than	vaccine	for	observed	reductions	in	an	
outcome.		Unfortunately,	the	literature	at	this	point	is	not	coordinated	with	respect	to	bias-
detection	and	trends	adjustment	strategies.		Furthermore,	more	effort	is	needed	to	assess	the	
extent	of	bias	favoring	publication	of	papers	with	expected	or	positive	results.				
	
We	have	not	comprehensively	drawn	attention	to	every	source	of	bias	in	each	of	the	three	
approaches	considered	here,	but	have	concentrated	on	those	that	are	particular	either	to	the	
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design	itself	or	to	the	class	of	VE	studies.	These	different	kinds	of	study	design	approaches	have	
different	strengths	and	limitations,	such	that	consistency	of	evidence	from	more	than	one	of	
these	may	be	more	compelling	than	repeated,	consistent	findings	from	one	study	design	(17).	
This	may	suggest	that	instead	of	the	classical		“hierarchy	of	evidence	quality”	the	strength	of	
evidence	on	a	question	should	be	evaluated	by	the	consistency	of	findings	across	study	designs	
(70,	71).		
	
In	conclusion,	challenges	lie	ahead	for	evaluating	best	practices	for	achieving	robust	unbiased	
results	from	observational	VE	studies.		Short	of	enormous	cluster-randomized	trials	at	the	time	
of	introduction	of	a	new	vaccine,	these	will	form	the	major	part	of	the	evidence	base	used	to	
evaluate	national	and	global	vaccine	program	effectiveness.		Great	strides	have	been	made	in	
recent	years,	but	this	is	an	unfinished	agenda.				
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TABLE	1:	Substantive	insights	from	published	literature	using	the	three	approaches	described	
in	this	paper	
	
Substantive	insights	from	negative-control	approaches	
	
• Showed	 that	 the	 vaccine-preventable	 burden	 of	 influenza	mortality	 has	 been	 overestimated	
due	to	confounding	(6,	14,	15)		
• Added	 confidence	 to	 several	 studies	 of	 cholera	 VE	 in	 outbreaks	 by	 showing	 that	 VE	 was	
estimated	to	be	not	statistically	different	from	zero	for	non-cholera	diarrhea	(65-67)		
	
Substantive	insights	from	test-negative	designs	
	
• Measured	 and	 compared	 VE	 of	 pandemic	 and	 seasonal	 vaccines	 in	 various	 seasons	
documenting	variation	across	seasons	and	sometimes	across	vaccines	within	a	season	in	studies	
where	classical	controls	were	not	employed	(45,	72,	73)		
• In	a	few	studies	where	different	control	groups	were	compared,	VE	estimates	were	sometimes	
similar	 for	 the	 test-negative	 design	 (74)	 and	 sometimes	 different	 (75);	 a	 comparison	 of	 per-
protocol	 results	 from	 RCTs	 versus	 estimates	 from	 test-negative	 observational	 studies	 of	 an	
influenza	vaccine	and	of	an	RSV	monoclonal	antibody	showed	close	concordance	(26)	.	
• Found	 that	 protection	 appears	 to	 decline	 over	 the	 course	 of	 influenza	 season,	 either	 due	 to	
waning	immunity	or	changing	composition	of	the	at-risk	group	(38-40)	
• Complemented	other	 study	designs	 to	produce	a	 consistent	 finding	 that	 the	2008-9	 seasonal	
influenza	vaccine	 increased	the	risk	of	 lab-confirmed	clinical	 infection	with	2009	pandemic	flu	
(17)		
• Confirmed	traditional	case-control	findings	of	high	VE	for	monovalent	and	pentavalent	rotavirus	
vaccines		in	children	(76-79)	
• Confirmed	 traditional	 case-control	 findings	 of	 likely	 waning	 immunity	 after	 the	 5th	 dose	 of	
pertussis	vaccine	in	children,	with	similar	results	to	those	found	with	traditional	controls	(80)		
• Suggested	 that	 classical	 case-control	 design	 overestimates	 VE	 of	 reduced	 acellular	 pertussis	
(Tdap)	vaccines	in	adolescents	and	adults	(81)	
• Confirmed	 traditional	 case-control	or	RCT	 findings	of	high	VE	 for	pneumococcal	 vaccines	 (28,	
29,	82)	
• Detected	low	measles	VE	among	children	in	Democratic	Republic	of	the	Congo	(83)	
	
Substantive	insights	from	ecologic	designs	
	
• Showed	 that	 the	 vaccine-preventable	 burden	 of	 influenza	mortality	 has	 been	 overestimated	
due	to	confounding	(15)	
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• Showed	 that	conjugate	vaccines	against	Hib	and	pneumococcal	disease	have	 large	direct	and	
indirect	effects	on	invasive	disease	hospitalizations	(2,	3,	84)		
• Showed	 reduced	 benefits	 due	 to	 serotype	 replacement	 which	 led	 to	 shift	 from	 PCV7	 to	
PCV13(69)		
• Demonstrated	effect	of	rotavirus	against	pediatric	diarrhea	mortality	in	Mexico	(4)	
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Table 2.  Newer observational study designs and strategies used to measure VE and 
identify and reduce bias 
 
 
Strategy Applicability 
to types of 
studies 
Summary Attractive 
feature 
Example of 
study that 
used this 
approach 
Conditions 
for validity 
Tradeoffs / 
Limitations 
Negative 
Control 
Outcome 
Case-control, 
Cohort, 
Ecological 
Apply 
parallel 
analysis to 
an outcome 
that should 
not be 
affected by 
vaccine to 
detect bias in 
VE 
estimation 
Improves 
confidence in 
validity of 
analytic 
approach 
(19) Negative 
control 
outcome must 
share 
confounders 
of the 
outcome of 
interest, but 
be causally 
unlinked to 
vaccine 
Can detect 
direction of 
bias under 
some 
assumptions, 
but can rarely 
correct for it 
Test-
Negative 
Case-
Control 
Often seen 
as a form of 
case-control 
study but  
(26)may be 
better 
understood 
as a form of 
cohort study 
(main text) 
Choose 
those who 
have been 
tested for 
clinical 
syndrome of 
interest but 
test negative 
for target 
pathogen as 
controls, to 
avoid 
confounding 
affecting 
propensity to 
get tested 
Easy, 
inexpensive 
access to 
control group 
in a 
surveillance 
setting 
 
(17, 28, 76-
79, 83)  
1. vaccine 
must not 
affect 
probability of 
conditions 
that lead to 
testing 
negative (eg 
other 
infections) 
either directly 
or indirectly 
2.Test highly 
sensitive and 
specific 
1. Creates 
selection bias 
by conditioning 
on testing, 
leading to 
noncausal 
associations 
among those 
tested 
between 
vaccination 
and infection 
2. Does not 
eliminate 
confounding 
due to 
vaccinees 
having 
different risk of 
infection from 
non-vaccinees, 
eg. due to 
place of 
residence or 
occupation 
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Ecological 
or Trends 
study:  
Ecological 
study 
Compare 
outcome 
over time or 
across 
populations 
with varying 
vaccine 
coverage to 
avoid 
assumption 
that 
vaccinated 
and 
unvaccinated 
are 
comparable 
Allows study 
of total effect 
of vaccine on 
population 
(direct + 
indirect 
(herd) effects 
 
(4) 
Any causes of 
time trends in 
the outcome 
other than 
vaccination 
must be 
identified and 
adjusted for, 
or 
extrapolated 
from time 
trends before 
the vaccine is 
introduced 
Major concern 
is ability to 
adjust for non-
vaccine time 
trends.  
Variability in 
epidemiologic 
context makes 
extrapolation 
of indirect/total 
effects 
questionable 
 
 
 
 
 
 
 
 
 
